Christy Santhosh on Muck Rack

Christy Santhosh

Verified
Kochi
As seen in: Reuters, MSN, MSN Canada, MSN Singapore, UOL, 7@7, ET Healthworld, MSN Malaysia, MSN Money Canada, MSN Philippines, MSN UK and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Christy

Contact Christy, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Moderna's mRNA flu vaccine faces FDA advisory panel scrutiny

|
By Christy Santhosh Verified, Mariam Sunny
| Yahoo Verified
FILE PHOTO: A sign marks the offices of Moderna in Cambridge, Massachusetts, U.S., July 22, 2025. REUTERS/Brian Snyder/File Photo By Christy Santhosh and Mariam Sunny June 18 (Reuters) - The U.S. Food and Drug Administration's advisory panel is set to vote on whether the benefits of Moderna's flu vaccine outweigh its risks in older ‌adults, after regulators reversed course on rejecting the drugmaker's initial application for the shot.
Open in Who Shared View Duplicates (47) Issue with article?

Moderna's mRNA flu vaccine faces FDA advisory panel scrutiny

|
By Christy Santhosh Verified, Mariam Sunny
| StreetInsider
FILE PHOTO: A sign marks the offices of Moderna in Cambridge, Massachusetts, U.S., July 22, 2025. REUTERS/Brian Snyder/File Photo June 18 (Reuters) - ‌The U.S. Food ​and Drug ​Administration's advisory panel is set to vote on whether the benefits of Moderna's flu vaccine outweigh its risks in older adults, after regulators reversed course on rejecting the drugmaker's initial application for ‌the shot.
Open in Who Shared Issue with article?

Moderna flu shot data may support use in older adults, US FDA staff says

|
By Christy Santhosh Verified, Mariam Sunny
| Sun Herald Verified
U.S. Food and Drug Administration staff reviewers said on Tuesday data demonstrating an immune response to Moderna's flu shot may support effectiveness in adults 65 years and older, sending its shares up 6%. Moderna's shot, mFlusiva, also showed superior relative vaccine efficacy versus a standard-dose flu vaccine in adults aged 50 to 64, they said in briefing documents published ahead of a meeting of the regulator's independent advisers on Thursday.
Open in Who Shared View Duplicates (3) Issue with article?
See all 4,115 licensed articles (4,202 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified